Overview Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases Status: Completed Trial end date: 2020-02-17 Target enrollment: Participant gender: Summary The purpose of the study is to evaluate the efficacy on lung function 6 months after one course of rituximab (2 infusions) and mycophénolate mofétil (MMF) treatment compared to one course of placebo and 6 months of MMF treatment in a broad range of patients with Interstitial Lung Diseases (ILD) non-responders to a first line immunosuppressive treatment. Phase: Phase 3 Details Lead Sponsor: University Hospital, ToursTreatments: Mycophenolate mofetilMycophenolic AcidRituximab